Previous close | 1.3500 |
Open | 1.4600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 35.00 |
Expiry date | 2025-01-17 |
Day's range | 1.3400 - 1.4600 |
Contract range | N/A |
Volume | |
Open interest | 9.3k |
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.